Pfizer - 35 Year Dividend History | PFE (2024)

FAQs

Is Pfizer a dividend trap? ›

Dividend stocks have been overvalued due to the influx of retirees seeking income, but Pfizer is an exception. Pfizer is trading at a good valuation and offers a decent yield with potential for growth. While not as straightforward as previous dividend buys, Pfizer is a solid medium-term investment option.

Pfizer has paid a quarterly dividend for 341 consecutive quarters -- that's a span of more than 85 years. The company has made a reliable dividend investment for decades, and while it hasn't always increased its payout, it has been a consistent income-generating investment during recessions and even wars.

Following a 42% correction in the past year, PFE stock, with a 5.84% dividend yield, appears promising for 2024. The company anticipates $60 billion in revenue, signaling 9% year-on-year growth, supported by a compelling product pipeline.

Pfizer Inc. ( PFE ) pays dividends on a quarterly basis. Pfizer Inc. ( PFE ) has increased its dividends for 15 consecutive years.

Pfizer is an undervalued pharma stock that trades at a low multiple, providing investors with a margin of safety. Part of a recession-resistant sector, it has raised dividends by more than 7% annually in the last 25 years, enhancing your effective yield over time.

Is PFE a Buy, Sell or Hold? Pfizer has a conensus rating of Moderate Buy which is based on 7 buy ratings, 10 hold ratings and 0 sell ratings.

Should You Buy Pfizer Stock? The worst of the slowdown looks to be over for Pfizer, and its non-COVID portfolio is growing at a reasonably good pace. Analysts expect its revenues to rise 2% and 5.6%, respectively, in 2024 and 2025, while its earnings per share are expected to rise 48% and 22% in these years.

Based on short-term price targets offered by 20 analysts, the average price target for Pfizer comes to $34.80. The forecasts range from a low of $27.00 to a high of $54.00. The average price target represents an increase of 37.06% from the last closing price of $25.39.

The bearish argument against buying Pfizer is factually correct in the sense that examining backward-looking financial metrics shows the company's current performance as being dramatically overshadowed by its performance from 2020 to mid-2022. It will take a long time for that situation to change.

How much will Pfizer stock cost in 2030? ›

Pfizer's next quarterly payment date is on Mar 01, 2024, when Pfizer shareholders who owned PFE shares before Jan 25, 2024 received a dividend payment of $0.42 per share. Add PFE to your watchlist to be reminded of PFE's next dividend payment. Does Pfizer have sufficient earnings to cover their dividend?

Pfizer has split its stock a total of five times: July 1, 1983: a 2-for-1 split. April 1, 1991: a 2-for-1 split. July 3, 1995: a 2-for-1 split.

Based on analysts offering 12 month price targets for PFE in the last 3 months. The average price target is $31.57 with a high estimate of $45 and a low estimate of $27.

Pfizer reported its results for the fourth quarter and full year of 2023. Full-year 2023 revenues were $58.5 billion, reflecting a 41% operational decline due primarily to the expected decline in COVID-19 revenues, while fourth-quarter revenues were $14.2 billion, reflecting a 42% operational decline.